Physician profile
Steven M Ruths
NPI 1093748519
$72,730.78
in general payments reported to CMS, 2019-2025
28 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,157 · 2020: $4,628 · 2021: $9,713 · 2022: $6,138 · 2023: $21K · 2024: $11K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Food and Beverage: $8,146 · Travel and Lodging: $2,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,912.50 |
| Food and Beverage | $8,145.52 |
| Travel and Lodging | $2,037.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $53,700.46 | 2021-2025 | Vraylar |
| Allergan, INC. | $5,207.28 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $4,673.96 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $1,215.86 | 2019-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $1,099.71 | 2019-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,015.09 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $984.82 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| E.R. Squibb & Sons, L.L.C. | $755.40 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $539.13 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $455.77 | 2019-2025 | Trintellix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $434.27 | 2020-2023 | |
| Neurocrine Biosciences, INC. | $376.40 | 2019-2025 | |
| Tris Pharma INC | $285.30 | 2019-2025 | Dyanavel Xr |
| Almatica Pharma LLC | $280.83 | 2021-2025 | Loreev Xr, Escitalopram |
| Axsome Therapeutics, INC. | $266.59 | 2023-2025 | Auvelity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $265.39 | 2019-2023 | Perseris |
| Ironshore Pharmaceuticals INC. | $235.50 | 2019 | |
| Janssen Pharmaceuticals, INC | $183.57 | 2019-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $171.62 | 2023 | Quviviq |
| Lundbeck LLC | $131.59 | 2019-2025 | Abilify Asimtufii, Abilify Maintena |
| Eisai INC. | $115.31 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.29 | 2024 | |
| Bausch Health US, LLC | $63.14 | 2019-2025 | Wellbutrin, Aplenzin |
| Supernus Pharmaceuticals, INC. | $59.90 | 2021-2022 | |
| Corium, LLC | $54.35 | 2023-2025 | Azstarys |
| Adlon Therapeutics L.P. | $30.38 | 2021 | |
| Orexo US, INC. | $21.60 | 2019 | |
| Neos Therapeutics, Lp | $15.27 | 2025 | Exxua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ruths listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.